In a decisive move aimed at safeguarding public health, the Union Ministry of Health and Family Welfare (MoHFW) has banned 156 Fixed Dose Combinations (FDCs) with immediate effect. These FDCs, which include common cold medications, fever reducers, and antibacterial, and antifungal drugs, have been deemed irrational and potentially harmful by an expert committee appointed by the Central government. The decision underscores the government’s commitment to eliminating unsafe and unjustifiable drug combinations from the market, ensuring that only effective and safe medications are available to the public.
Understanding Fixed Dose Combinations (FDCs)
Fixed Dose Combinations are pharmaceutical products that combine two or more active ingredients in a single dosage form. While some FDCs are developed to improve patient compliance, enhance therapeutic efficacy, or reduce the risk of drug resistance, not all combinations are rational or necessary. When FDCs are not supported by clinical evidence or lack therapeutic justification, they can pose significant risks to patients, including adverse drug interactions, increased side effects, and the potential for ineffective treatment.
The Ban: A Result of Rigorous Examination
The recent ban on 156 FDCs follows a thorough examination by the Drugs Technical Advisory Board (DTAB), which is the highest statutory decision-making body on technical matters related to drugs in India. The DTAB, after careful review, concluded that there was “no therapeutic justification for the ingredients contained in these FDCs” and that their use “may involve risk to human beings.” The Ministry’s orders, issued on August 2, 2024, state that the decision to ban these drugs was taken in the larger public interest under Section 26A of the Drugs and Cosmetics Act, 1940.
This section grants the Central government the authority to regulate or restrict the manufacture, sale, or distribution of drugs if they are deemed unsafe, ineffective, or irrational.
Impact on Major Pharmaceutical Players
The ban impacts several well-known pharmaceutical companies, including Sun Pharmaceuticals, Dr. Reddy’s Laboratories, Cipla, Alkem Laboratories, Mankind Pharma, Torrent Pharmaceuticals, and Eris Lifesciences. These companies produce some of the FDCs that have now been prohibited. Notably, 22 of the banned formulations contain Naphazoline, a common decongestant used in eye drops, which has been flagged for its potential risks.
A History of FDC Regulation
This is not the first time the Indian government has taken action against irrational FDCs. In March 2016, the government banned 344 FDCs following recommendations from the Professor Kokate Committee, which highlighted the risks posed by these combinations when safer alternatives were available. This action was in response to concerns raised by the Department-related Parliamentary Standing Committee on Health and Family Welfare, which noted that some state licensing authorities had issued manufacturing licenses for FDCs without prior clearance from the Central Drugs Standard Control Organisation (CDSCO). This led to the availability of many untested FDCs in the market, potentially putting patients at risk.
Despite the government’s efforts, the ban faced legal challenges from several stakeholders, including major pharmaceutical companies. The Delhi High Court quashed the 2016 notification, prompting the Central government to appeal to the Supreme Court. In December 2017, the Supreme Court referred the case of 349 FDCs back to the DTAB for further examination, except 15 pre-1988 approved FDCs and 17 FDCs with approval from the Drug Controller General of India (DCGI).
The Ongoing Battle Against Irrational FDCs
The recent ban on 156 FDCs is part of the government’s ongoing efforts to cleanse the pharmaceutical market of irrational and unsafe drug combinations. By prohibiting these FDCs, the Ministry aims to prevent the potential risks associated with their use, such as adverse drug reactions and therapeutic inefficacy. The decision also reflects the government’s resolve to prioritize patient safety over commercial interests.
While the ban represents a significant step forward, it also raises important questions about the regulatory processes that allowed these FDCs to enter the market in the first place. The fact that several FDCs were licensed without proper clearance underscores the need for stricter regulatory oversight and more rigorous testing of drug combinations before they are approved for sale.
Conclusion: A Win for Public Health
The ban on 156 Fixed Dose Combinations is a clear victory for public health in India. It sends a strong message to the pharmaceutical industry that patient safety cannot be compromised, and that only rational, evidence-based drug combinations will be tolerated. Moving forward, it is crucial for the government to continue monitoring the market for irrational FDCs and to take swift action when necessary.
This decision also highlights the importance of informed, evidence-based policymaking in healthcare. By relying on expert committees and thorough examination processes, the government has demonstrated its commitment to protecting the health and well-being of its citizens. As the battle against irrational FDCs continues, the ultimate goal remains clear: to ensure that every medication available to the public is safe, effective, and justified.
To register for our next masterclass please click here https://linktr.ee/docpreneur
